Hemab Therapeutics Holdings

Hemab Therapeutics Holdings (Ticker: COAG US) develops treatments given under the skin for rare blood-clotting disorders. Founded in 2020, the company is incorporated in Delaware. Its lead candidate, sutacimig (HMB-001), is being developed for Glanzmann thrombasthenia. It completed Phase 2 trials and was described as ready to move into Phase 3 testing. HMB-002 is in Phase 1/2 trials for Von Willebrand disease. The company reported no revenue and a net loss of $63.91 million for the year ended December 31, 2025.

The scheduled listing date on Nasdaq was May 1, 2026. The proposed offering comprises 11,760,000 shares at an indicative price range of $16.00–18.00 per share. At the indicative range midpoint, the base offering would represent $199.92 million in gross proceeds, excluding any unexercised over-allotment.

Goldman Sachs, Jefferies, and Evercore ISI are joint managers.